One of the busiest IPO weeks of the year has capped off with another four biotechs expected to make their public debuts Friday.
After Lyell, Verve and Molecular Partners all priced earlier in the week, ATAI Life Sciences, Century Therapeutics, Ambrx Biopharma and Cyteir Therapeutics each followed suit with nine-figure raises after market close Thursday. All that effort has driven the combined biotech IPO raise close to $9 billion, per the Endpoints News tally.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,